Analyst Price Targets — IMDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 1:48 pm | — | Lake Street | $12.00 | $5.33 | TheFly | Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street |
| November 11, 2025 9:51 am | Mike Matson | Needham | $9.00 | $6.80 | StreetInsider | Insight Molecular Diagnostics Inc. (IMDX) PT Raised to $9 at Needham |
| May 21, 2025 12:42 pm | Thomas Flaten | UBS | $8.00 | $3.07 | TheFly | OncoCyte price target raised to $8 from $5 at Lake Street |
| April 24, 2024 10:38 am | Mike Matson | Needham | $4.25 | $2.38 | StreetInsider | OncoCyte Corp (OCX) PT Raised to $4.25 at Needham |
| December 1, 2022 9:13 am | — | Lake Street | $10.00 | $9.44 | Benzinga | Lake Street Downgrades OncoCyte to Hold, Lowers Price Target to $0.5 |
| November 18, 2022 5:05 am | — | Piper Sandler | $10.00 | $8.52 | Benzinga | Piper Sandler Downgrades OncoCyte to Neutral, Lowers Price Target to $0.5 |
| August 17, 2022 9:42 pm | David Westenberg | Piper Sandler | $30.00 | $17.48 | TheFly | OncoCyte price target raised to $1.50 from $1.40 at Piper Sandler |
| August 11, 2022 10:43 am | — | Lake Street | $60.00 | $19.27 | Benzinga | Lake Street Maintains Buy on OncoCyte, Lowers Price Target to $3 |
| August 11, 2022 5:31 am | — | Needham | $42.00 | $19.02 | Benzinga | Needham Maintains Buy on OncoCyte, Lowers Price Target to $2.1 |
| May 15, 2022 9:15 pm | David Westenberg | Piper Sandler | $28.00 | $22.60 | TheFly | OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler |
Latest News for IMDX
NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.
Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58 Recent studies advanced science of molecular diagnostic testing for transplanted organ rejection, published in Clinical Chemistry, Transplant International, American Journal of Transplantation and Nephrology Dialysis Transplantation, among others NASHVILLE,…
-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-
NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry, the premier, peer-reviewed scientific publication of the Association for Diagnostics & Laboratory Medicine. The article highlights the concordant performance between iMDx's digital-PCR-based flagship transplant monitoring…
American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA alone GraftAssure assay doubles reliability of positive results in screening cohort In for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80% NASHVILLE, Tenn.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMDX.
U.S. House Trading
No House trades found for IMDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.